Zentiva closes takeover of Alvogen’s business in Romania, Bulgaria, Croatia
Pan-European pharmaceutical company Zentiva Group said on April 7 that it has completed the acquisition of U.S.-based Alvogen’s Central and Eastern European business in Bulgaria, Croatia, Romania and several other countries.
The deal adds to Prague-based Zentiva’s continuing organic growth, reinforcing its commercial footprint in Bulgaria, Poland and Romania expanding its presence into additional new markets including Croatia, Hungary, Kazakhstan, Russia, Ukraine and the Western Balkans, the company said.
“With this acquisition, we bring together two of the leading branded generic and OTC businesses in the CEE region,” said Nick Haggar, chief executive of Zentiva.
Policymakers Cut Central Bank Base Rate by 50 bp to 7.75%
Bulgaria's Household Income, Spending Rise 20% in 2023
Spar Magyarország Revenue Climbs Close to 16% in 2023
Hungary Launches HUF 15 bln Tourism Sector Support Program
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
